Wedbush Analysts Reduce Earnings Estimates for Unum Therapeutics Inc (NASDAQ:UMRX)
Unum Therapeutics Inc (NASDAQ:UMRX) – Wedbush decreased their Q3 2019 earnings per share (EPS) estimates for Unum Therapeutics in a report released on Tuesday, August 13th. Wedbush analyst D. Nierengarten now forecasts that the company will earn ($0.30) per share for the quarter, down from their previous forecast of ($0.26). Wedbush currently has a “Outperform” rating and a $13.00 target price on the stock. Wedbush also issued estimates for Unum Therapeutics’ Q4 2019 earnings at ($0.23) EPS, FY2019 earnings at ($1.27) EPS, FY2020 earnings at ($0.83) EPS, FY2021 earnings at ($1.39) EPS, FY2022 earnings at ($1.17) EPS and FY2023 earnings at $0.04 EPS.
Several other research firms have also recently commented on UMRX. HC Wainwright restated a “buy” rating on shares of Unum Therapeutics ...